11a, 12-DERIVATIVES OF TETRACYCLINE COMPOUNDS

Abstract

11a,12-dehydrotetracycline compounds are described.

1 . A compound selected from the group consisting of: 
       
         
           
           
               
               
           
         
       
       and pharmaceutically acceptable salts, esters, prodrugs and enantiomers thereof. 
     
     
         2 . A pharmaceutical composition comprising a compound of  claim 1  and a pharmaceutically acceptable carrier. 
     
     
         3 . The pharmaceutical composition of  claim 2 , wherein said compound is present in an amount effective to ameliorate a disease selected from: bacterial infection, multiple sclerosis, central pontine myelinolysis, leukodystrophy, acute disseminated encephalomyelitis, progressive multifocal leukoencephalopathy, and subacute sclerosing panencephalitis. 
     
     
         4 . A method for ameliorating a disease selected from: bacterial infection, multiple sclerosis, central pontine myelinolysis, leukodystrophy, acute disseminated encephalomyelitis, progressive multifocal leukoencephalopathy, and subacute sclerosing panencephalitis in a subject in need thereof, comprising administering to said subject an effective amount of a compound of  claim 1 , such that said disease is ameliorated. 
     
     
         5 . The method of  claim 4 , wherein said subject is a mammal. 
     
     
         6 . The method of  claim 4 , wherein said subject is a human. 
     
     
         7 . The method of  claim 4 , wherein said disease is bacterial infection. 
     
     
         8 . The method of  claim 4 , wherein said disease is central pontine myelinolysis. 
     
     
         9 . The method of  claim 4 , wherein said disease is leukodystrophy. 
     
     
         10 . The method of  claim 4 , wherein said disease is acute disseminated encephalomyelitis. 
     
     
         11 . The method of  claim 4 , wherein said disease is progressive multifocal leukoencephalopathy. 
     
     
         12 . The method of  claim 4 , wherein said disease is subacute sclerosing panencephalitis. 
     
     
         13 . The method of  claim 4 , wherein said disease is multiple sclerosis. 
     
     
         14 . The method of  claim 13 , wherein said multiple sclerosis is relapsing or remitting multiple sclerosis, primary progressive multiple sclerosis, or secondary progressive multiple sclerosis. 
     
     
         15 . The tetracycline compound of  claim 1 , wherein the tetracycline compound is an anti-oxidant.